We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s New Quality Office Needed to Strengthen Preapproval GMPs
FDA’s New Quality Office Needed to Strengthen Preapproval GMPs
September 14, 2012
BALTIMORE — CDER’s proposed new Office of Pharmaceutical Quality (OPQ) is needed to promote good manufacturing practice (GMP) standards in the preapproval setting — standardizing GMP assessments throughout a drug’s life cycle.